Micro Cap Surges Following WHO Approval

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, June 24, 2025

An Ireland-based healthcare company is stealing the show so far during Tuesday’s session after it was announced that the company received World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing activities of its high-volume TrinScreen™ HIV rapid test, according to a press release.

Traders wasted little time snatching up shares of Trinity Biotech plc (Nasdaq:TRIB) following the recent announcement, with shares of the micro cap reaching up to $0.7778/share (+41.16%) at the early session high. This move could be a confirmation of recent support.

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Ireland of which it derives a majority of its revenues from the Americas segment.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.